Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre 12-week Randomised Double-blind Placebo Controlled Feasibility Trial of Sodium Benzoate and/or N-acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder.

NCT03510741 is registered in ClinicalTrials.gov with Pakistan Institute of Living and Learning as lead sponsor.

NCT NCT03510741
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03510741 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre 12-week Randomised Double-blind Placebo Controlled Feasibility Trial of Sodium Benzoate and/or N-acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder.
Lead sponsor
Pakistan Institute of Living and Learning
Phase
Phase 2
Overall status
Completed
Start date
January 1, 2019
Completion date
March 30, 2021
Enrollment
64 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective disorder, schizophrenia, schizophreniform disorders